Americans now say they approve of free trade by 64%-27%, a margin of better than two to one. That's up from 57%-37% early in Trump's presidency, and 51%-41% near the end of...Politicsread more
Trump said Cook made a "good case" that it would be difficult for Apple to pay tariffs, when Samsung does not face the same hurdle because much of its manufacturing is in...Technologyread more
Kudlow pointed to strong retail sales and low unemployment as signs that the U.S. economy remained strong.Marketsread more
The yield on the benchmark 10-year Treasury note briefly fell below the 2-year rate on Wednesday, a phenomenon in the bond market known as yield curve inversion, which is...Marketsread more
"I don't want to do business at all because it is a national security threat," Trump told reporters.Technologyread more
Despite aggressive strides, Waymo needs one thing before their self-driving cars become a seriously useful transportation system: people. We talked to the ones closest to it.Technologyread more
The MacBook Pro recall and its subsequent ban from flights underscores the increasing brand risk from problems with lithium-ion batteries.Technologyread more
Experts say the timing of Amazon executives' contributions to Rep. David Cicilline likely reflect the company's heightened urgency over growing regulatory scrutiny.Technologyread more
CNBC combed through Wall Street research to see which stocks are still a buy after their earnings reports.Marketsread more
Coinbase security chief Philip Martin explains, "Possession of a key is possession of your currency. What that means is that you can't revoke a cryptocurrency key, if that key...Technologyread more
Fraud investigator Harry Markopolos' accusations extended beyond GE's management to actuaries, auditors and analysts who he claims overlooked billions in liabilities.Marketsread more
The same type of machine learning technology that can automatically organize Google photos might someday be used to prevent sudden death.
That's the vision of Vic Gundotra, chief executive officer of medical technology start-up AliveCor and a former executive at . Gundotra announced on Wednesday that his company is teaming up with the Mayo Clinic to develop tools to screen for a heart rhythm condition called Long QT that causes thousands of deaths per year.
AliveCor is also announcing its third round of investment from the Mayo Clinic in the past nine months, bringing its total funding from all of its investors to just more than $45 million. The company declined to comment on the details of its funding from Mayo.
AliveCor is best known for its Band-Aid-sized sensor called Kardia Mobile, which attaches to a smartphone. When users put their fingers on Kardia's pads, it takes readings called electrocardiograms that indicate problems with the electrical activity of the heart. Anyone can buy the device for $99.
The company is also developing a version of its Kardia device for the Watch.
Gundotra said he came out of retirement to join AliveCor because he believed that artificial intelligence could be used for disease prevention. "Deep neural networks can uncover signals that human doctors often can't see," he said.
AliveCor already has the green light from the U.S. Food and Drug Administration to analyze electrocardiograms to detect an irregular heartbeat called atrial fibrillation. So it is turning its attention to Long QT syndrome, an electrical condition in the heart that causes it to beat irregularly. The inherited version kills 3,000 to 4,000 people in the U.S. every year. (There's also a version that can be caused by commonly prescribed drugs.)
"The new partnership is another endeavor to look at the electrocardiogram signal and find another secret," Gundotra said. "The secret we are after is genetic Long QT."
Such technology could save lives, suggested Mayo Clinic's Michael Ackerman, given that the genetic form often goes undiagnosed until it's too late. "But when we find it, our treatments are incredibly effective," he said.
This technology is still in the investigational phase, stressed Ackerman, and Mayo and AliveCor will need to demonstrate that it's accurate and cost-effective. But his team at Mayo are hoping within a few years to develop a cheap and simple screening using AliveCor's Kardia Mobile. The idea is that anyone could use it, including coaches, primary care doctors and pharmacists.
Ultimately, if such a feat is possible, Ackerman hopes that the electrical heart cycle will be the "next vital sign," which is as common to measure as blood pressure.
"The goal is to prevent the sudden death of young people because of QT-related heart issues," he said.